Oculus Innovative Sciences Announces Appointment of Russell Harrison to Board
PETALUMA, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS), today announced the appointment of Russell
("Russ") Harrison to its board of directors, effective February 26, 2014.
"We are pleased to welcome Russ to our board," stated Jim Schutz, CEO of
Oculus. "His extensive business background,including strong executive
experience in strategicplanning, will bea terrific resource as we re-focus
our energy on increasing revenue growth and longer term planning."
Harrison is the founding principal of The Leadership Group, a firm
specializing in strategic change and executive coaching for U.S. and
international corporations. He began his business career with then-fledgling
Electronic Data Systems. In the years after, Russ served as senior vice
president at Bank of America, as chief information officer at McKesson and at
SITA Telecommunications Holdings (a global communications firm in Paris), and
as founding president of AMR Information Systems, an American Airlines
information technology subsidiary. He has served in the role of chief
executive officer for a number of publicly traded and private companies in
both the information technology and medical device sectors.
Harrison received an MBA with honors from Saint Mary's College of California,
and has served as president of the board of regents, and as chairman of the
board of trustees at Saint Mary's. He earned his bachelor's degree in
economics from the University of Southern California and also served as a
captain in the United States Marine Corps.
About Oculus Innovative Sciences
Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in 31
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets, while raising the
standard ofpatient care and lowering overall healthcare costs. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found
Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the commercial and technology progress and futurefinancial performance
of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company").
These forward-looking statements are identified by the use of words such as
"anticipates,""believes," "expects," and "intends,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, the
uncertainties associated with an initial public offering of a separate public
company, and other risks detailed from time to time in the Company's filings
with the Securities and Exchange Commission including the annual report on
Form 10-K for theyear ended March 31, 2013. Oculus Innovative Sciences
disclaims any obligation to update these forward-looking statements except as
required by law.
Oculus and Microcyn® Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.
High-resolution photo of Mr. Harrison available upon request.
CONTACT: Media and Investor Contact:
Oculus Innovative Sciences, Inc.
Director of Public and Investor Relations
Press spacebar to pause and continue. Press esc to stop.